Lonza snapped up Codiak Biosciences' exosome manufacturing facility in Massachusetts, gaining access to technology that turns drug molecules into exosomes in order to selectively deliver treatments to target tissues and reduce toxicity. The two companies are forming a Center of Excellence for the development of exosome production and analytics technologies.
Cell and gene therapy: The next frontier in pharmaceutical services
acs.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acs.org Daily Mail and Mail on Sunday newspapers.
Altimmune Expands AdCOVID™ Manufacturing Collaboration With Lonza · BioBuzz
biobuzz.io - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biobuzz.io Daily Mail and Mail on Sunday newspapers.
Published: Mar 12, 2021
Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune’s COVID-19 Vaccine Candidate at its Houston Facility
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2021 (GLOBE NEWSWIRE)
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has expanded its previously-announced AdCOVID manufacturing collaboration with Lonza. Under the expanded agreement, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, Altimmune’s single-dose intranasal vaccine candidate for COVID-19, at its facility near Houston, Texas.
“Manufacturing capacity for COVID-19 vaccines has been severely constrained, and this limitation has presented considerable challenges for vaccine developers,” said Dr. Vyjayanthi Krishnan, Ph.D., Vice President of Product Development for Altimmune. “By expanding our Lonza collaboration and commissioning our own d